Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer.
about
Overview of breast cancer collaborative stage data items--their definitions, quality, usage, and clinical implications: a review of SEER data for 2004-2010.Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers.A synergistic antiproliferation effect of curcumin and docosahexaenoic acid in SK-BR-3 breast cancer cells: unique signaling not explained by the effects of either compound alone.Apoptosis - associated genes and their role in predicting responses to neoadjuvant breast cancer treatment.Aberrant expression of Arpin in human breast cancer and its clinical significance.New network topology approaches reveal differential correlation patterns in breast cancer.Disparities in race/ethnicity and socioeconomic status: risk of mortality of breast cancer patients in the California Cancer Registry, 2000-2010Breast cancer medications and vision: effects of treatments for early-stage disease.The Influence of Socioeconomic Status on Racial/Ethnic Disparities among the ER/PR/HER2 Breast Cancer Subtypes.Correlation of Hormone Receptor Expression with Histologic Parameters in Benign and Malignant Breast Tumors.Expression of antigen processing and presenting molecules in brain metastasis of breast cancer.Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer.Which breast cancer decisions remain non-compliant with guidelines despite the use of computerised decision support?Metastasis tumor-associated protein 2 enhances metastatic behavior and is associated with poor outcomes in estrogen receptor-negative breast cancer.Impact of breast cancer subtypes on 3-year survival among adolescent and young adult women.OPG and PgR show similar cohort specific effects as prognostic factors in ER positive breast cancerThe Epigenetic Landscape of Promoter Genome-wide Analysis in Breast CancerBreast Cancer Outcomes as Defined by the Estrogen Receptor, Progesterone Receptor, and Human Growth Factor Receptor-2 in a Multi-ethnic Asian Country.H3K4 acetylation, H3K9 acetylation and H3K27 methylation in breast tumor molecular subtypes.Disparities in receipt of adjuvant radiation therapy after breast-conserving surgery among the cancer-reporting regions of California.Validity of St Gallen risk categories in prognostication of breast cancer patients in Southern Sri Lanka.A retrospective prognostic evaluation analysis using the 8th edition of the American Joint Committee on Cancer staging system for breast cancer.Racial/ethnic and socioeconomic differences in short-term breast cancer survival among women in an integrated health system.
P2860
Q30870747-05FED078-CB4E-4ADD-BCA9-D3D39BA96368Q33757796-68E2F413-DE7B-41A4-BBC5-35DCB2C7F02EQ33878984-CDFA8DC2-80A1-4553-B88C-781D637265EAQ34114155-B9D08BBA-2447-4F45-8587-0F83390413AFQ34504538-85F8CF06-864E-4020-A6FE-C5FA36816E1EQ34941536-440C4E1E-B809-41D6-A6CE-86A9A1ED6DBEQ35003673-EB4D3FAB-32E9-478D-9F2E-6A99EFC90810Q35496778-2E9870DA-EE5E-4CEE-A0DE-E44D0B52244EQ35962877-46652E48-AE72-4513-8073-EFF4F2AE8E1DQ35964928-2FF6D0E7-75DC-4A05-91A5-DCD82D1EB1FFQ36002622-208ACA43-0B2D-40E7-8BE6-2DD006D7C427Q36494250-741362B0-FBF3-4984-8C8E-53262E0B04AFQ37185832-D740F0A6-9F28-403A-89B1-AC1FC45276CFQ37671724-AE37A80F-9B3B-4A06-A93D-E564AE87C9A8Q37690054-2E216DC2-9CDC-42EF-A519-3024D3417F89Q41135180-33E20BE3-D5CC-4D59-8C6D-55D7A108806CQ41139971-9A8CB885-1F82-4808-8E3F-033D57DA4EBDQ41616925-A70D1D1B-3BA7-458C-84BA-343B57E957C5Q42496397-EA7BD271-21BD-4F5B-949C-A6D8032A6958Q45982831-7112EF0B-9A37-4C6E-893F-229BEC73B6DDQ47547742-D94CF306-6939-49E1-A1C9-5A8690B70416Q49505532-F60B100F-0873-406F-8AEF-DDE8C3134750Q53805731-8063B6FE-146F-4FAB-B243-4668AA0B6201
P2860
Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Use of ER/PR/HER2 subtypes in ...... ement for early breast cancer.
@ast
Use of ER/PR/HER2 subtypes in ...... ement for early breast cancer.
@en
Use of ER/PR/HER2 subtypes in ...... ement for early breast cancer.
@nl
type
label
Use of ER/PR/HER2 subtypes in ...... ement for early breast cancer.
@ast
Use of ER/PR/HER2 subtypes in ...... ement for early breast cancer.
@en
Use of ER/PR/HER2 subtypes in ...... ement for early breast cancer.
@nl
prefLabel
Use of ER/PR/HER2 subtypes in ...... ement for early breast cancer.
@ast
Use of ER/PR/HER2 subtypes in ...... ement for early breast cancer.
@en
Use of ER/PR/HER2 subtypes in ...... ement for early breast cancer.
@nl
P2093
P2860
P356
P1433
P1476
Use of ER/PR/HER2 subtypes in ...... ement for early breast cancer.
@en
P2093
Carol Parise
Katrina Bauer
Vincent Caggiano
P2860
P2888
P356
10.1186/1471-2407-10-228
P407
P577
2010-05-21T00:00:00Z
P5875
P6179
1030682398